DR-050 Discovery and Clincal Characterization of Cancer Driver Mutations in Noncoding regions
Cancer genomes typically harbor a substantial number of somatic mutations. However, only few of these mutations actually contribute to tumor development. To identify these so-called driver mutations, large-scale aggregated sequencing datasets are needed. Over the past decade, the search for driver mutations has been mostly focussed on coding regions. Substantially less is known whether and to which degree mutations in non-coding regions are functionally involved in tumor formation. With the drop in sequencing costs over the past years, it became possible to sequence the entire genomes of large cohorts of cancer patients (e.g. the dataset provided by Hartwig Medical Foundation). However, the avaialalbity of these datasets has not been met with the of algorithms that are particularly designed to the underlying biology of these data yet. The goal of this project is to develop a statistical framework which systematically identifies driver mutations in non-coding regions in aggregated whole-genome sequencing data. For this purpose, we will particularly consider the biological differences between coding an non-coding regions, in order to specifically taylor our algorithm to non-coding regions. Applying this refined approach to ~2500 Whole Genome Sequencing data, we will systematically characterize which mutations in non-coding regions are relevant to oncogenesis.
Eliezer van Allen Dana-Farber Cancer Institute USA
Terug naar nieuwsMeer nieuws
In de media: GENAYA mikt op duizend complete DNA-profielen
Bron: Oncologie Up-to-date 2023 vol 14 nummer 5 Het vorig jaar gestarte project GENAYA heeft als doel bij 1.000 jongeren/jongvolwassenen …
New cancer treatment options created by full DNA-analysis
Nature publication reports study by Netherlands Center for Personalized Cancer Treatment showing benefits for targeted treatments outside registered indications 2 …
Deelname aan GENAYA, hoe werkt dat voor de patiënt?
Rhodé Bijlsma, internist-oncoloog in het UMC Utrecht: “De patiënt wordt voorgelicht en geeft dan toestemming voor deelname. Daarna nemen we …
Een complete genetische analyse zou onderdeel moeten zijn van de standaarddiagnostiek bij iedere patiënt met kanker. Dat draagt bij aan een beter, afgestemd behandeladvies. Zo verminderen we over- en onderbehandeling, maken we tegelijkertijd de zorg kosten-effectiever en houden we hem betaalbaar.